Scott Dreyer
Net worth: 2 M $ as of 31/05/2026
Net worth: 2 M $ as of 31/05/2026
Scott Dreyer is Chief Commercial Officer & Executive VP at Collegium Pharmaceutical, Inc. since 2018.
Formerly, Mr. Dreyer was Vice President-US Hospital & Oncology Sales at Merck & Co., Inc. from 1994 to 2013, Chief Marketing Officer & Vice President at Biogen, Inc. from 2014 to 2016, and Senior VP-Marketing & Commercial Operations at The Medicines Co. from 2016 to 2017.
Mr. Dreyer completed an undergraduate degree at the University of Messiah in 1994.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/03/2026 | 71,770 ( 0.22% ) | 2 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Corporate Officer/Principal | 10/07/2018 |
| Companies | Position | End |
|---|---|---|
| THE MEDICINES COMPANY | Sales & Marketing | 01/12/2017 |
| BIOGEN INC. | Sales & Marketing | 01/09/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2013 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
University of Messiah
University of Messiah Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions